RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

32564 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-30

Study Completion Date

2036-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise.

Although there are some examples of well-established national registries on RADs in EU, the lack of recommendations for Rare disease registries implementation and the lack of standards for interoperability has led to the fragmentation or unavailability of data on prevalence, survival, main clinical manifestations or treatments in most of the European countries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Integrative Diagnosis for SCD and Other RADs

NCT07206095

Sickle Cell Disease Thalassaemia Congenital Dyserythropoietic Anemia (CDA) +6 more

RECRUITING

ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19

NCT06831799

Hemoglobinopathies Sickle Cell Disease Sickle Cell Anemia +21 more

COMPLETED

European Rare Blood Disorders Platform (ENROL)

NCT06250595

Anemia Bone Marrow Failure Bleeding Disorder +9 more

RECRUITING

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820

β-thalassemia Transfusional Iron Overload

COMPLETED PHASE1

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

NCT00564941

Myelodysplastic Syndromes Beta-Thalassemia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Rare Anaemia Disorders European Epidemiological Platform (RADeep) is an initiative endorsed by the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet) under the frame of the European Blood Disorders Platform (ENROL), the ERN-EuroBloodNet umbrella platform officially endorsed by the European Hematology Association (EHA) for European patients' registries on rare haematological diseases. RADeep will share pseudonymised level data with ENROL.

RADeep supports the standardized collection of data of patients affected by any RADs at the European level, maximizing public benefit from data on RADs opened-up with the only restriction needed to guarantee patient rights and confidentiality, in agreement with the General Data Protection Regulation and applicable laws for cross-border sharing of personal data. RADeep has the following major objectives:

1. To collect and describe the demographics, disease-management, and treatment outcomes of patients diagnosed with RADs
2. To perform observational studies concerning research questions and to present outcomes in the fields of health related to organ damage and risk stratification for identification of trial cohorts for new drugs and/or development of research projects
3. To promote harmonization and best practices in the prevention, diagnosis, treatment and follow-up of RADs patients by the dissemination of reliable Guidelines and the translation of research results into clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease Thalassemia Hemolytic; Anemia, Hereditary, Due to Enzyme Disorder Anemia Due to Membrane Defect CDA Sideroblastic Anemia Constitutional Aplastic Anemia Iron Metabolism Disorders Hereditary Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sickle cell anaemia and other related sickle diseases

Patients with sickle cell disease and related diseases in current regular follow-ups in European-Union health centers